Eugia US recalls one lot of vancomycin injection over particulate matter
The company is pulling lot 3VM26026A of Vancomycin Hydrochloride for Injection USP 1.25g/Vial-30mL from hospitals and healthcare facilities nationwide.
Eugia US LLC, formerly known as Auro Medics Pharma LLC, announced a voluntary nationwide recall on November 6, 2026, of a single lot of injectable vancomycin. The recall covers lot number 3VM26026A of Vancomycin Hydrochloride for Injection USP 1.25g/Vial-30mL (Single Dose Vial), pulled to the hospital/healthcare facility/user level due to the presence of particulate matter.1
The notice was issued from East Windsor, New Jersey, and identifies the manufacturer under its current and former corporate names.
The underlying FDA record does not provide further detail in the supplied excerpt, including the specific nature or extent of the particulate contamination, the distribution footprint of the affected lot, or any reported adverse events. Readers seeking additional specifics, such as instructions for providers holding the affected product or contact information for returns, should consult the full FDA recall notice once available.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.